382147 Histone Deacetylase Inhibitor I

382147
  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

       

      Contact Customer Service

      Overview

      Replacement Information
      Description
      OverviewA cell-permeable, benzamide analog that acts as a histone deacetylase inhibitor (IC50 = 2 µM). In in vitro and in vivo. Induces differentiation, transcription of growth factor β II receptor (TβRII), and inhibits proliferation of human breast cancer cells (~1 µM).
      Catalogue Number382147
      Brand Family Calbiochem®
      SynonymsMS-275, N-(2-Aminophenyl)-4-[N-(pyridine-3-ylmethoxycarbonyl)aminomethyl]benzamide
      References
      ReferencesSimonini, M.V., et al. 2006. Proc. Natl. Acad. Sci. USA 103, 1587. Onyia, J.E., et al. 2004. J. Pharmacol. Exp. Ther. 309, 369. Lee, B.I., et al. 2001. Cancer Res. 61, 931. Saito, A., et al. 1999. Proc. Natl. Acad. Sci. USA 96, 4592. Suzuki, T., et al. 1999. J. Med. Chem. 42, 3001.
      Product Information
      FormTan solid
      Hill FormulaC₂₁H₂₀N₄O₃
      Chemical formulaC₂₁H₂₀N₄O₃
      Structure formula ImageStructure formula Image
      Applications
      Biological Information
      Primary Targethistone deacetylase
      Primary Target IC<sub>50</sub>2 µM
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstituion, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Histone Deacetylase Inhibitor I Certificates of Analysis

      TitleLot Number
      382147

      References

      Reference overview
      Simonini, M.V., et al. 2006. Proc. Natl. Acad. Sci. USA 103, 1587. Onyia, J.E., et al. 2004. J. Pharmacol. Exp. Ther. 309, 369. Lee, B.I., et al. 2001. Cancer Res. 61, 931. Saito, A., et al. 1999. Proc. Natl. Acad. Sci. USA 96, 4592. Suzuki, T., et al. 1999. J. Med. Chem. 42, 3001.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision12-December-2008 RFH
      SynonymsMS-275, N-(2-Aminophenyl)-4-[N-(pyridine-3-ylmethoxycarbonyl)aminomethyl]benzamide
      DescriptionA cell-permeable, benzamide analog that acts as a histone deacetylase inhibitor (IC50 = 2 µM) and exhibits anti-tumor properties. Suitable for use in both in vitro and in vivo applications. Induces transcription of transforming growth factor β II receptor (TβRII), but not TβRI, and inhibits proliferation of human breast cancer cell lines (~1 µM).
      FormTan solid
      Intert gas (Yes/No) Packaged under inert gas
      Chemical formulaC₂₁H₂₀N₄O₃
      Structure formulaStructure formula
      Purity≥95% by HPLC
      SolubilityDMSO (10 mg/ml)
      Storage -20°C
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstituion, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.
      Toxicity Standard Handling
      ReferencesSimonini, M.V., et al. 2006. Proc. Natl. Acad. Sci. USA 103, 1587. Onyia, J.E., et al. 2004. J. Pharmacol. Exp. Ther. 309, 369. Lee, B.I., et al. 2001. Cancer Res. 61, 931. Saito, A., et al. 1999. Proc. Natl. Acad. Sci. USA 96, 4592. Suzuki, T., et al. 1999. J. Med. Chem. 42, 3001.